Dr. Jacob Schachter

Prof. Jacob Schachter is one of Israel's leading medical oncologists specialising in melanoma and cancer immunotherapy. He heads the Ella Lemelbaum Institute for Melanoma and Immunotherapy at Sheba Medical Center, Tel HaShomer, and holds a professorial appointment at Tel Aviv University Faculty of Medicine. He has more than 25 years of clinical and research experience in melanoma, checkpoint inhibitor therapy, and tumour-infiltrating lymphocyte therapy.

CancerFax can coordinate medical-record review and consultation support for international patients seeking a second opinion or treatment evaluation from Prof. Schachter at Sheba Medical Center, subject to hospital availability and case acceptance. Patients should share their biopsy reports, imaging, mutation testing, prior treatment history, and current clinical summary.

Prof. Schachter treats the full range of melanoma presentations, including cutaneous melanoma, metastatic melanoma, stage III and stage IV disease, melanoma with brain or visceral metastases, recurrent melanoma, and melanoma that has progressed after prior immunotherapy or targeted therapy. He also sees patients with other skin cancers requiring systemic oncology treatment.

Prof. Schachter is known for his work with immune checkpoint inhibitors including pembrolizumab (anti-PD-1), nivolumab, and ipilimumab (anti-CTLA-4), as well as combination immunotherapy strategies. He was an investigator in the KEYNOTE-006 trial comparing pembrolizumab with ipilimumab in advanced melanoma, which contributed to global treatment standard changes. He is also associated with the TIL therapy programme at the Ella Lemelbaum Institute.

Tumour-infiltrating lymphocyte therapy, or TIL therapy, is a form of personalised adoptive cell therapy in which immune cells are extracted from the patient's tumour, expanded in laboratory conditions, and reinfused to fight the cancer. The Ella Lemelbaum Institute at Sheba Medical Center runs an active TIL therapy programme for selected patients with metastatic melanoma, particularly those who have progressed on standard treatments. CancerFax can coordinate eligibility assessment for interested patients.

Submit your complete medical records through CancerFax using the Send Your Reports button. The CancerFax team will review the documents, prepare a structured case summary, and coordinate the consultation or second-opinion request with Sheba Medical Center, subject to availability. Patients should ideally include biopsy and histopathology reports, BRAF/NRAS/KIT mutation results, PET-CT or MRI imaging reports, prior treatment summaries, and current clinical status.